Psychopharmacology

, Volume 233, Issue 2, pp 187–197 | Cite as

Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients

Original Investigation

Abstract

Rationale

The factors underlying the variability in the results of randomized, placebo-controlled clinical trials (RPCCT) assessing pharmacological interventions for adults with attention deficit hyperactivity disorder (ADHD) are not fully understood.

Methods

A systematic review and meta-analysis of RPCCT comparing pharmacological treatment and placebo in adults with ADHD was carried out. The study outcomes were all-cause treatment discontinuation, efficacy on ADHD symptoms, and safety. Patient-, intervention-, and study design-related covariates were collected. Meta-regression methods were applied.

Results

Forty-four studies involving 9952 patients were included. All-cause treatment discontinuation was slightly higher with pharmacological treatment than with placebo (odds ratio (OR) = 1.18; 95 % confidence interval (CI) 1.02, 1.36; p = 0.003). A better outcome on all-cause treatment discontinuation was observed in studies that provided concomitant psychotherapy when compared to those that did not (rate of OR (ROR) = 0.68, p = 0.048). Pharmacological treatment was efficacious for reducing ADHD symptoms (standardized mean difference (SMD) = 0.45; 95 % CI 0.37, 0.52; p < 0.00001), with stronger intervention effects found in studies investigating stimulant drugs (difference of SMD (Diff SMD) = 0.18, p = 0.017), in shorter studies (Diff SMD = −0.01, p = 0.044), and when clinician-rated scales were used (Diff SMD = 0.44, p < 0.0001). Pharmacological treatment was associated with more frequent adverse events (AEs) (OR = 2.29; 95 % CI 1.97, 2.66; p = 0.006). Studies with a lead-in phase and with a higher proportion of patients previously treated with stimulants were associated with a better safety outcome (ROR = 0.59, p = 0.017; ROR = 0.98, p = 0.036, respectively).

Conclusion

Pharmacological treatment provides mild symptom improvement but is associated with frequent AEs and higher treatment discontinuation than placebo, particularly when no concomitant psychotherapy is administered. Stimulants appear more efficacious than non-stimulant drugs and the former should be preferred over the latter. The efficacy of pharmacological treatment should be monitored over time because it may decrease progressively.

Keywords

Attention deficit hyperactivity disorder Systematic review Meta-analysis Meta-regression Efficacy Safety Placebo-controlled clinical trial 

Supplementary material

213_2015_4099_MOESM1_ESM.doc (666 kb)
ESM 1(DOC 665 kb)

References

  1. Asherson P, Bushe C, Saylor K, Tanaka Y, Deberdt W, Upadhyaya H (2014) Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol 28:837–46PubMedPubMedCentralCrossRefGoogle Scholar
  2. Bae JM (2014) Meta-epidemiology. Epidemiol Health 25:36, e2014019Google Scholar
  3. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRefGoogle Scholar
  4. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA (1995) A random effects regression model for meta-analysis. Stat Med 14:395–411PubMedCrossRefGoogle Scholar
  5. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M (2006) Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 67:524–40PubMedCrossRefGoogle Scholar
  6. Biederman J, Petty CR, Woodworth KY, Lomedico A, Hyder LL, Faraone SV (2012) Adult outcome of attention-deficit/hyperactivity disorder: a controlled 16-year follow-up study. J Clin Psychiatry 73:941–50PubMedCrossRefGoogle Scholar
  7. Bolea-Alamañac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, Heal D, Müller U, Nash J, Santosh P, Sayal K, Sonuga-Barke E, Young SJ, British Association for Psychopharmacology (2014) Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 28:179–203PubMedCrossRefGoogle Scholar
  8. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) (2011) Canadian ADHD practice guidelines. 3rd edn. TorontoGoogle Scholar
  9. Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, Casas M (2011) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 25:157–69PubMedCrossRefGoogle Scholar
  10. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:110–129Google Scholar
  11. Cohen J (1988) Statistical power analysis in the behavioural sciences, 2nd edn. Lawrence Erlbaum Associated, HillsdaleGoogle Scholar
  12. Cunill R, Castells X, Tobias A, Capellà D (2015) Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol 29:15–23PubMedCrossRefGoogle Scholar
  13. Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG (2015) Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet S0140–6736(14):61684–6. doi:10.1016/S0140-6736(14)61684-6 Google Scholar
  14. Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P (2011) Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann Intern Med 155:39–51PubMedCrossRefGoogle Scholar
  15. Epstein T, Patsopoulos NA, Weiser M (2014) Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 9:CD005041. doi:10.1002/14651858.CD005041.pub2 PubMedGoogle Scholar
  16. Higgins JPT, Green S (2011a) The Cochrane Collaboration tool for assessing risk of bias. In: Cochrane handbook for systematic reviews of interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration Available from www.cochrane-handbook.org
  17. Higgins JPT, Green S (2011b) How to include multiple groups from one study. In: Higgins JPT, Green S (eds), Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration Available from www.cochrane-handbook.org
  18. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analysis. BMJ 327:557–560PubMedPubMedCentralCrossRefGoogle Scholar
  19. Jerome L, Segal A, Habinski L (2006) What we know about ADHD and driving risk: literature review, meta-analysis and critique. J Can Adolesc Psychiatry 15:105–25CrossRefGoogle Scholar
  20. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716–23PubMedPubMedCentralCrossRefGoogle Scholar
  21. Klein RG, Mannuzza S, Olazagasti MA, Roizen E, Hutchison JA, Lashua EC, Castellanos FX (2012) Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry 69:1295–303PubMedPubMedCentralCrossRefGoogle Scholar
  22. Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S (2009) Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23:733–44PubMedCrossRefGoogle Scholar
  23. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P (2010) European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 10:67PubMedPubMedCentralCrossRefGoogle Scholar
  24. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV (2006) Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 81:137–48PubMedCrossRefGoogle Scholar
  25. Levin FR, Evans SM, Brooks DJ, Garawi F (2007) Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 87:20–9PubMedCrossRefGoogle Scholar
  26. Maneeton N, Maneeton B, Srisurapanont M, Martin SD (2011) Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci 65:611–7PubMedCrossRefGoogle Scholar
  27. Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD (2014) Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD. Drug Des Devel Ther 8:1685–93PubMedPubMedCentralCrossRefGoogle Scholar
  28. Mannuzza S, Klein RG, Moulton JL 3rd (2008) Lifetime criminality among boys with attention deficit hyperactivity disorder: a prospective follow-up study into adulthood using official arrest records. Psychiatry Res 160:237–46PubMedPubMedCentralCrossRefGoogle Scholar
  29. MTA Cooperative Group (2004) National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113:762–769CrossRefGoogle Scholar
  30. National Institute for Health and Clinical Excellence (NICE) (2008) Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. Clinical guidelines CG72Google Scholar
  31. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D, Atomoxetine/Methylphenidate Comparative Study Group (2008) Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 165:721–30PubMedCrossRefGoogle Scholar
  32. Pérez-Mañá C, Castells X, Torrens M, Capellà D, Farre M (2013) Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev 9:CD009695. doi:10.1002/14651858.CD009695.pub2 PubMedGoogle Scholar
  33. Peterson K, McDonagh MS, Fu R (2008) Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl) 197:1–11CrossRefGoogle Scholar
  34. Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA (2015) Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry 56:345–65PubMedCrossRefGoogle Scholar
  35. Review Manager (RevMan) Version 5.3 (2014) Copenhagen: The Nordic Cochrane Centre, The Cochrane CollaborationGoogle Scholar
  36. Schwartz S, Correll CU (2014) Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry 53:174–87PubMedCrossRefGoogle Scholar
  37. Seixas M, Weiss M, Müller U (2012) Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol 26:753–65PubMedCrossRefGoogle Scholar
  38. Sharf J, Primavera LH, Diener MJ (2010) Dropout and therapeutic alliance: a meta-analysis of adult individual psychotherapy. Psychotherapy (Chic) 47:637–45CrossRefGoogle Scholar
  39. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 194:204–11PubMedCrossRefGoogle Scholar
  40. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S (2005) A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57:456–63PubMedCrossRefGoogle Scholar
  41. StataCorp (2011) Stata statistical software: release 12 [Computer program] (2011) College Station, TX: StataCorpGoogle Scholar
  42. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 339:b2880. doi:10.1136/bmj.b2880 PubMedPubMedCentralCrossRefGoogle Scholar
  43. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29:15–31PubMedCrossRefGoogle Scholar
  44. Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S (1999) Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 66:295–305PubMedCrossRefGoogle Scholar
  45. Taylor A, Deb S, Unwin G (2011) Scales for the identification of adults with attention deficit hyperactivity disorder (ADHD): a systematic review. Res Dev Disabil 2:924–38CrossRefGoogle Scholar
  46. Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI (2011) Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 72:1660–8PubMedCrossRefGoogle Scholar
  47. Undurraga J, Baldessarini RJ (2012) Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37:851–64PubMedPubMedCentralCrossRefGoogle Scholar
  48. Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C, 31001074–ATT2001 Study Investigators (2012) Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs 26:421–34PubMedCrossRefGoogle Scholar
  49. Weiss MD, Gadow K, Wasdell MB (2006) Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry 67:38–45PubMedCrossRefGoogle Scholar
  50. Willcutt EG (2012) The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 9:490–9PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • R. Cunill
    • 1
  • X. Castells
    • 2
  • A. Tobias
    • 3
  • D. Capellà
    • 2
  1. 1.Parc Sanitari Sant Joan de DéuFundació Sant Joan de DéuBarcelonaSpain
  2. 2.Clinical Pharmacology Unit, TransLab Research Group, Department of Medical SciencesUniversitat de GironaGironaSpain
  3. 3.Institute of Environmental Assessment and Water Research (IDAEA)Spanish Council for Scientific Research (CSIC)BarcelonaSpain

Personalised recommendations